Dynavax starts HBV Phase II

Dynavax (Berkeley, Calif.) began a Canadian Phase II trial of its ISS (immunostimulatory DNA sequence) vaccine to prevent hepatitis B virus (HBV) infection. The primary endpoint of the trial will be s...